News
Inceptua announced that Paul Wituschek has been appointed President North America
Inceptua announced that Paul Wituschek has been appointed President North America. To further strengthen its position as a leading pharmaceutical company and service partner, Inceptua appoints Paul Wituschek as President North America effective 1 January, 2020.
Paul will take on...
Clinical Trials
Janssen to Acquire Investigational Bermekimab from XBiotech
Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, announced that it has entered a definitive agreement to acquire all rights to the investigational compound bermekimab from XBiotech Inc. Bermekimab is an anti-IL-1alpha monoclonal antibody (mAb) in...
News
Recipharm invests in its US inhalation development service
Recipharm, the contract development and manufacturing organisation (CDMO), has invested USD 450,000 into its Research Triangle Park (RTP), North Carolina, US facility to install a SprayVIEW® system that will support inhalation and nasal product development.
The newly acquired system was...
News
Sanofi Lines Up for Potential Approval of Cold Agglutinin Disease Treatment
Following positive results from a pivotal Phase III trial assessing the safety and efficacy of sutimlimab in people with primary cold agglutinin disease (CAD), Sanofi is making plans to seek regulatory approval of the medication in the United States.
France-based...
News
Pistoia Alliance Report ‘Futurecasts’ a Decade of Change for Life Sciences and Healthcare
The Pistoia Alliance, a global, not-for-profit organisation that works to lower barriers to innovation in life sciences R&D, announced the publication of a new report into the future of the life science and healthcare industries: ‘2030: Life sciences and...
News
Inceptua Medicines Access and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the US
Onconova Therapeutics, Inc , a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), and Inceptua Medicines Access (a business unit of the Inceptua Group), a global pharmaceutical...
Drug Research
Spotlight on Abzena’s Developability Platform during Antibody Engineering & Therapeutics 2019
Abzena is showcasing its new Developability Service, enabling biotechnology and pharmaceutical companies to improve lead selection and de-risk cell line development, at Antibody Engineering & Therapeutics 2019 being held 9–13 December, on Booth #414 at the Marriott Marquis San...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.